Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTK-567
- Development stage
- Phase 2
- Lead developer
- Wakayama Medical University
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
TTK-567 is a cancer-testis antigen-derived peptide vaccine consisting of the amino acid sequence SYRNEIAYL. It is an HLA-A*2402-restricted epitope derived from the TTK protein kinase (also known as Monopolar spindle 1 or Mps1), which is frequently overexpressed in various malignancies, including esophageal squamous cell carcinoma (ESCC). Developed by Wakayama Medical University, TTK-567 functions as an immunotherapy by stimulating cytotoxic T lymphocytes (CTLs) to recognize and eliminate cancer cells expressing the TTK antigen. In clinical trials, it has been evaluated in combination with other tumor-associated antigen peptides (such as URLC10-177) and adjuvants like CpG-7909 (Agatolimod) and Montanide ISA 51 for the treatment of advanced or recurrent esophageal cancer.
- Other names
- SYRNEIAYLTTK-567 peptide vaccineTTK567 peptide vaccineTTK 567 peptide vaccineTTK-567 peptideTTK567 peptideTTK 567 peptide
02
Targets
HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)γδ TCR (T-cell receptor)TTK (TTK protein kinase)
Beyond the preview
Go deeper on TTK-567.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTK-567.